pharma · Immunotherapy · Opioid Analgesic Adverse Reaction
Second Affiliated Hospital of Soochow University
Second Affiliated Hospital drug portfolio — 11 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Portfolio lens on 11 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Second Affiliated Hospital drug portfolio — 11 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
US regulatory status: approved. Molecular target: Vascular endothelial growth factor A, long form.
Development asset linked to Second Affiliated Hospital in public FDA and regional records. Molecular target: Cytotoxic T-lymphocyte protein 4.
US regulatory status: approved. Molecular target: Programmed cell death 1 ligand 1.
Nervous system (N06) compound in Second Affiliated Hospital's portfolio. Molecular target: Glutamate [NMDA] receptor.
Development asset linked to Second Affiliated Hospital in public FDA and regional records. Mechanism: DNA topoisomerase II alpha inhibitor.
Development asset linked to Second Affiliated Hospital in public FDA and regional records.
US regulatory status: approved. Molecular target: Cytotoxic T-lymphocyte protein 4.
US regulatory status: approved. Molecular target: Programmed cell death protein 1.
Development asset linked to Second Affiliated Hospital in public FDA and regional records. Mechanism: Mu opioid receptor agonist.
Development asset linked to Second Affiliated Hospital in public FDA and regional records.
US regulatory status: approved. Molecular target: Integrin alpha-4/beta-7.